within Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA01_Verteporfin;

model Verteporfin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 6.397222222222222e-05,
    adminDuration = 600,
    adminMass = 6 / 1000000,
    adminCount = 1,
    Vd = 0.00017999999999999998,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00029,
    k12 = 8.127777777777777e-05,
    k21 = 8.127777777777777e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Verteporfin</td></tr><tr><td>ATC code:</td><td>S01LA01</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>6</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.18</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.29</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Verteporfin is a photosensitizing agent used in photodynamic therapy to treat neovascular (wet) age-related macular degeneration and pathological myopia. It is approved and used clinically for ocular neovascular conditions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults aged 18-85 years without significant comorbidities after intravenous infusion over 10 minutes.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01LA01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Verteporfin;
